Our vision is to develop a novel cancer therapy that gives patients with poor prognosis and aggressive, resistant, metastasized tumors a better option. This is, according to us, best based on targeting the MYC oncoprotein, the main driver of such high-risk tumors.
We are cancer researchers at Karolinska Institutet and Linköping University that have spent almost 15 years to build the basis for drugging the "undruggable" but highly desirable target MYC.
We have identified several potential drug candidates, developed methods, and obtained knowledge of how to target MYC, which we are now bringing together into MyCural Therapeutics to develop ground-breaking new cancer therapy for patients with MYC-driven aggressive high-risk tumors.
We are cancer researchers at Karolinska Institutet and Linköping University that have spent almost 15 years to build the basis for drugging the "undruggable" but highly desirable target MYC.
We have identified several potential drug candidates, developed methods, and obtained knowledge of how to target MYC, which we are now bringing together into MyCural Therapeutics to develop ground-breaking new cancer therapy for patients with MYC-driven aggressive high-risk tumors.
Location: Sweden, Uppsala
Employees: 1-10
Founded date: 2022